Abstract
Gaucher disease is inherited as an autosomal recessive disorder. The absence of β-glucocerebrosidase whose purpose is to cleave the glucose from ceramide results in accumulation of glucocerebroside; storage of this glycolipid results in Gaucher disease. There is tremendous clinical heterogeneity: prediction of onset of symptoms (if at all), which organs will be affected, and the degree of severity of the signs and symptoms are areas of current research. Lysosomal storage diseases may be treatable by enzyme replacement therapy. Enzyme replacement for Gaucher disease has been attempted intermittently since the middle 1970s but was not successful until removal of sugars to expose the inner mannose residues allowed the targeting of the enzyme to macrophages via mannose receptors. The use of the recombinant imiglucerase (Cerezyme™) as intravenous therapy has been safe and effective for the visceral symptoms and signs of Gaucher disease in more than 5000 patients world-wide for more than 18 years. Nonetheless, beyond enzymes not being able to traverse the blood-brain barrer, dependence on a single modality is problematic since not all patients are responders, some develop adverse events, and supply may not be forthcoming for non-medical reasons. Thus, the availability of new enzymatic preparations, velaglucerase alfa (VPRIV™) and taliglucerase alfa (UPLYSO™), as well as alternative modalities such as substrate reduction and pharmacological chaperones, are important additions to the management portfolio of this disease.
Keywords: Eliglustat tartrate, enzyme replacement therapy, Gaucher disease, imiglucerase, isofagomine tartrate, miglustat, pharmacological chaperones, substrate reduction therapy, taliglucerase alfa, velaglucerase alfa, ceramide, Lysosomal storage diseases, mannose receptors, recombinant imiglucerase (Cerezyme) as intravenous therapy, chaperones
Current Pharmaceutical Biotechnology
Title: Recent Advances in Treatment Approaches to Gaucher Disease
Volume: 12 Issue: 6
Author(s): Deborah Elstein and Ari Zimran
Affiliation:
Keywords: Eliglustat tartrate, enzyme replacement therapy, Gaucher disease, imiglucerase, isofagomine tartrate, miglustat, pharmacological chaperones, substrate reduction therapy, taliglucerase alfa, velaglucerase alfa, ceramide, Lysosomal storage diseases, mannose receptors, recombinant imiglucerase (Cerezyme) as intravenous therapy, chaperones
Abstract: Gaucher disease is inherited as an autosomal recessive disorder. The absence of β-glucocerebrosidase whose purpose is to cleave the glucose from ceramide results in accumulation of glucocerebroside; storage of this glycolipid results in Gaucher disease. There is tremendous clinical heterogeneity: prediction of onset of symptoms (if at all), which organs will be affected, and the degree of severity of the signs and symptoms are areas of current research. Lysosomal storage diseases may be treatable by enzyme replacement therapy. Enzyme replacement for Gaucher disease has been attempted intermittently since the middle 1970s but was not successful until removal of sugars to expose the inner mannose residues allowed the targeting of the enzyme to macrophages via mannose receptors. The use of the recombinant imiglucerase (Cerezyme™) as intravenous therapy has been safe and effective for the visceral symptoms and signs of Gaucher disease in more than 5000 patients world-wide for more than 18 years. Nonetheless, beyond enzymes not being able to traverse the blood-brain barrer, dependence on a single modality is problematic since not all patients are responders, some develop adverse events, and supply may not be forthcoming for non-medical reasons. Thus, the availability of new enzymatic preparations, velaglucerase alfa (VPRIV™) and taliglucerase alfa (UPLYSO™), as well as alternative modalities such as substrate reduction and pharmacological chaperones, are important additions to the management portfolio of this disease.
Export Options
About this article
Cite this article as:
Elstein Deborah and Zimran Ari, Recent Advances in Treatment Approaches to Gaucher Disease, Current Pharmaceutical Biotechnology 2011; 12 (6) . https://dx.doi.org/10.2174/138920111795542624
DOI https://dx.doi.org/10.2174/138920111795542624 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Noninvasive Mechanical Ventilation in the Treatment of Community-Acquired Pneumonia
Current Respiratory Medicine Reviews RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry The ABCB1 C3435T Polymorphism is Associated with Triglyceride Reduction in Atorvastatin-treated Uygur Patients with Coronary Heart Disease and Dyslipidemia: An Observational Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews Pharmacological Activities of Components Contained in <i>Camellia</i> Oil and <i>Camellia</i> Oil Cake and their Applications in Various Industries
Current Traditional Medicine Development and Validation of a Sensitive UPLC-Q-TOF-MS/MS for the Measurement of Nine Components in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Studies with Xuanfei Baidu Granules
Current Drug Metabolism Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review
Current Diabetes Reviews Nutritional Antioxidants Mechanisms of Action, Analyses of Activities and Medical Applications
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Carbohydrate Reward and Psychosis: An Explanation For Neuroleptic Induced Weight Gain and Path to Improved Mental Health?
Current Neuropharmacology Recent Progress on Chemical Biology of Pluripotent Stem Cell Selfrenewal, Reprogramming and Cardiomyogenesis
Recent Patents on Regenerative Medicine Medical Devices for Telemedicine and Home Care Applications
Recent Patents on Biomedical Engineering (Discontinued) Realizing the Potential of Health-Promoting Rosehips from Dogroses (Rosa sect. Caninae)
Current Bioactive Compounds Nanotechnology Based Diagnostic and Therapeutic Strategies for Neuroscience with Special Emphasis on Ischemic Stroke
Current Medicinal Chemistry Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Drug-Induced Hypokalaemia
Current Drug Safety Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Thioredoxin-1 is a Novel and Attractive Therapeutic Approach for Various Diseases Including Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets